pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk is a pharma organization headquartered in bagsværd, DK. Primary therapeutic focus areas include Diabetes, Congenital Bleeding Disorder, Acquired Bleeding Disorder, Overweight, Cardiorespiratory arrest at bir
Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
KCT10/2022-LEASH
Approved · small molecule · Hyperlipidaemia
KCT10/2022-LEASH for Hyperlipidaemia is a Approved program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Internal code KCT10/2022-LEASH
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novo Nordisk A/S
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Hyperlipidaemia
- Status
- active
- Trials
- 1